The Accelerating Medicines Partnership (AMP) is a bold new venture between the NIH, 10 biopharmaceutical companies and several non-profit organizations to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease. The ultimate goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.
AMP will begin with three to five year pilot projects in three disease areas:
- Alzheimer’s disease
- Type 2 diabetes
- Autoimmune disorders of rheumatoid arthritis and systemic lupus
- Erythematosus (lupus)